Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
OpenEvidence and Tandem are linking clinical AI with prior authorization automation. Read what this could change for prescribing, access, and workflow.
Can VR LIFE and H2 Global Group scale from European validation to global MedTech relevance? Read the deeper analysis now.
Allevion Medical’s Vantage won FDA 510(k) clearance for lumbar decompression. Read what this may change for spinal stenosis workflow, adoption, and risk.
Spacelabs Healthcare and DEPTH Health are pairing Rothman Index analytics with patient flow tools. Read what this could change for hospitals.
ATL Medical and OMNIVISION have expanded arthroscopy imaging integration. Read what this means for OEM speed, quality, and device development.
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.
Peri has launched a perimenopause wearable, but can symptom tracking become clinical-grade insight? Read the deeper industry analysis now.
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.
Syra Health and Nora Mental Health are linking AI triage with teletherapy in Indiana. Read why this could reshape digital mental health access.